Blog · Evidence, in plain language

GLP-1 medicines and mood, checked against the evidence.

Patients ask about this at follow-up visits more than almost anything else in the news: can the diabetes and weight-loss medicines called GLP-1s change your mood, or make depression worse? Regulators spent two years on that question. This post walks through what they found, what it means, and what it does not mean.

By Karel Winner, DNP, PMHNP-BC · Published October 4, 2026

Why this question needed a real answer

GLP-1 medicines, such as semaglutide and tirzepatide, are prescribed for type 2 diabetes and for weight management, and millions of people now take them. In 2023, regulators began receiving reports of suicidal thoughts in some people taking these medicines. Reports like that are a signal to investigate, not an answer. A report cannot separate the medicine from the condition it treats, and both obesity and diabetes come with higher rates of depression to begin with. So the U.S. Food and Drug Administration and European regulators opened formal reviews, and the FDA eventually ran its own analysis of the trial data.

What the FDA found

In January 2026, the FDA published the results. The agency pooled 91 placebo-controlled trials covering 107,910 patients and found no increased risk of suicidal thoughts or behaviors in people taking GLP-1 medicines, and no increase in anxiety, depression, irritability, or psychosis either. It then ran a second, much larger check using health records for about 2.24 million people, comparing new GLP-1 users with users of another diabetes medicine class, and again found no increased risk of intentional self-harm, including in people who had both obesity and diabetes.

On the strength of that work, the FDA asked the makers of the weight-loss versions (Wegovy, Saxenda, and Zepbound) to remove the suicidal thoughts warning from their labels. The agency's advice to patients was plain: keep taking your prescribed medicine, and discuss any concerns with your clinician.

What the trial evidence adds

The regulators' conclusion lines up with the published research. A 2026 meta-analysis pooled 86 randomized trials with 133,378 participants and found psychiatric problems at essentially the same rate in the GLP-1 groups and the comparison groups. Depression, anxiety, and suicide measures each showed no significant increase. A Swedish national study took a different approach, comparing people with depression and anxiety to themselves: during the months they were taking a GLP-1 medicine, they had fewer episodes of worsening illness than during the months they were not. That is an interesting signal, and the study's authors are careful to say it is not proof the medicines protect mood. Trials designed to test that question directly have not been done yet.

What this does not mean

Three limits matter. First, these medicines are not treatments for depression or anxiety, and nothing in this research makes them one. Second, group averages are not a promise about any one person: people can feel worse on a new medicine for ordinary reasons, including nausea, rapid changes in eating, or life simply being hard at the same time. Third, a mood change after starting any medicine is always worth raising, whatever the studies say. Research describes populations. Your prescriber treats you.

What careful prescribers do with this

Tell every clinician involved in your care if you start a GLP-1 medicine, including the one who manages your psychiatric medicines. These medicines slow stomach emptying, which can change how some oral medicines are absorbed, and a prescriber working from an incomplete medication list is working half blind. Expect mood to be asked about at follow-up visits either way, because that is standard monitoring, not suspicion. And never stop a psychiatric medicine because of a headline, in either direction: the reassuring headlines are not a reason to change a working regimen, just as the frightening ones were not.

The bottom line

The best current evidence says GLP-1 medicines do not raise the risk of depression or suicidal thoughts for the average patient, and regulators on two continents have now said so after doing the work. Your own care still runs on your history and your response, which is why the follow-up visit matters more than the news cycle.

Sources

This post is based on the sources below. The numbers quoted are the studies' own numbers.

U.S. Food and Drug Administration, Drug Safety Communication, January 13, 2026: the FDA review of GLP-1 medicines and suicidal thoughts and behaviors, and its request to remove that warning language from the weight-loss labels. Medscape's report of the FDA announcement.

Han and colleagues, Diabetes, Obesity and Metabolism (2026): a systematic review and meta-analysis of 86 randomized trials with 133,378 participants, on GLP-1 medicines and psychiatric disorders. PubMed record.

Swedish national cohort study, The Lancet Psychiatry (2026): GLP-1 use and worsening mental illness in people with depression and anxiety. The Lancet Psychiatry.

Systematic review of psychiatric safety, Cureus (2026): 11 studies covering more than 4.9 million patients. PubMed record.

Please read this part

Nothing in this post is medical advice, and reading it does not create a treatment relationship. Research results describe averages across very large groups; they cannot predict what any one medicine will do for you. If you take a GLP-1 medicine, or are thinking about starting one, and you notice a change in your mood, tell the clinician who prescribes for you. If a thought of harming yourself appears, treat it as urgent and use the crisis options below, whatever you believe caused it.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or see the crisis page.